 the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.  the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.
 il trattamento di pazienti adulti affetti da artrite reumatoide attiva di grado da moderato a grave quando la risposta ai farmaci anti-reumatici modificanti la malattia (Disease Modifying Anti- rheumatic Drugs – DMARDs), compreso il metotressato, risulta inadeguata.